FindTrial
Sign In

Tislelizumab Injection

DRUG11 trials

Sponsors

XiangNing Fu, The Fourth Affiliated Hospital of Zhejiang University School of Medicine, First Affiliated Hospital Xi'an Jiaotong University, Henan Cancer Hospital, Nanjing Leads Biolabs Co.,Ltd

Conditions

AdolescentAdvanced MelanomaAdvanced Solid TumourAdvanced Squamous Non-Small Cell Lung CarcinomaBrentuximab VedotinChildClassical Hodgkin LymphomaLung Cancer (NSCLC)

Phase 1

A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors
CompletedNCT05516914
Nanjing Leads Biolabs Co.,LtdMalignant Tumors
Start: 2022-09-01End: 2026-01-30Updated: 2026-04-01

Phase 2

Neoadjuvant Immunotherapy in Early Stage Non-small-cell Lung Cancer Presenting as Synchronous Ground-glass Nodules
CompletedNCT04047186
XiangNing FuMultiple Pulmonary Nodules
Start: 2019-07-01End: 2025-05-30Updated: 2025-09-23
Neoadjuvant Arterial Embolization Chemotherapy Combined PD-1 Inhibitor for Locally Advanced Rectal Cancer
NCT05420584
The Fourth Affiliated Hospital of Zhejiang University School of MedicineRectal Neoplasms
Start: 2022-11-29End: 2025-10-31Target: 83Updated: 2023-05-11
Comprehensive Bladder Preservation Therapy on Patients With Muscle Invasive Bladder Cancer
Not yet recruitingNCT05445648
First Affiliated Hospital Xi'an Jiaotong UniversityUrinary Bladder Neoplasms
Start: 2023-02-28End: 2026-02-28Target: 65Updated: 2022-12-28
PD-1 Antibody Tislelizumab Combined With Dacarbazine in the Treatment of Advanced Melanoma
NCT05466474
Henan Cancer HospitalAdvanced Melanoma
Start: 2022-12-30End: 2024-04-30Target: 40Updated: 2023-10-24
Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC
RecruitingNCT06379087
Ji YonglingNon-Small Cell Lung Cancer
Start: 2024-05-01End: 2026-12-31Target: 20Updated: 2025-07-10
Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment
RecruitingNCT06563245
Children's Cancer Group, ChinaAdolescent, Brentuximab Vedotin, Child +6
Start: 2024-09-25End: 2039-11-15Target: 96Updated: 2026-03-19
An Open-label, Single-arm Clinical Study of Stapokibart Injection in Combination with Tislelizumab Injection in Patients with Non-Small Cell Lung Cancer
Not yet recruitingNCT06883552
Sichuan UniversityLung Cancer (NSCLC)
Start: 2025-10-01End: 2026-10-01Target: 21Updated: 2025-03-19
A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]
RecruitingNCT07331155
Nanjing Leads Biolabs Co.,LtdAdvanced Solid Tumour
Start: 2026-02-26End: 2028-12-26Target: 110Updated: 2026-03-09
A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]
Not yet recruitingNCT07390383
Nanjing Leads Biolabs Co.,LtdAdvanced Solid Tumour
Start: 2026-04-01End: 2028-05-30Target: 110Updated: 2026-04-01

Phase 3

TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer.
NCT05718167
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Advanced Squamous Non-Small Cell Lung Carcinoma
Start: 2023-02-28End: 2025-10-31Target: 570Updated: 2023-02-14

Related Papers

Phase 3 study of benmelstobart in combination with chemotherapy followed by sequential combination with anlotinib for the first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer (sq-NSCLC).
Journal of Clinical Oncology2025-05-282 citations
Updated efficacy, safety and biomarker analysis of a phase 2 study of LBL-007 (alcestobart, an anti-LAG-3 mAb) combined with tislelizumab (an anti–PD-1 mAb) and chemotherapy in previously untreated recurrent or metastatic nasopharyngeal carcinoma (R/M NPC).
Journal of Clinical Oncology2025-05-28
Neoadjuvant hypofractionated radiotherapy plus tislelizumab with anlotinib followed by adjuvant tislelizumab with anlotinib in patients with resectable non-small cell lung cancer (NSCLC): Preliminary analysis of a phase II trial (NEO-PIONEER).
Journal of Clinical Oncology2025-05-28
Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody tislelizumab with or without chemotherapy in patients with advanced nasopharyngeal cancer and other malignant tumors: A phase Ib/II dose escalation/expansion study.
Journal of Clinical Oncology2024-06-011 citations
Neoadjuvant Arterial Embolization Chemotherapy Combined PD-1 Inhibitor for Locally Advanced Rectal Cancer (NECI Study): a protocol for a phase II study
BMJ Open2023-03-012 citations
[Application of Neoadjuvant Immuno-chemotherapy in NSCLC].
2021-04-015 citations